Floatz logo

bc008-1a

Glioblastoma WHO Grade IV

Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Glioblastoma WHO Grade IV cohort.

Asset / SponsorPhaseRating
Quisinostat
Nader Sanai
Early Phase 1C
BMS-986504
Nader Sanai
Early Phase 1C

Same molecule, other indications

bc008-1a is also rated in:

glioblastomaDormant
CC
Indicative ·
43 / 100
View asset →
esophageal cancerDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →